SUBSCRIBE
SUBSCRIBE

Nick Paul Taylor

Nick is a freelance writer who has been reporting on the global life sciences industry since 2008. With a BSc in biology, Nick writes about the science and business of biopharma and medtech for numerous healthcare publications. He can be reached at nick.paul.taylor@gmail.com or on LinkedIn.

Pictured: Rare disease ribbon with cut-outs of people
Rare diseases
Regeneron wins FDA approval to challenge Ipsen for rare bone disease market
Regeneron’s Pasatru is the second fibrodysplasia ossificans progressiva drug approved in the U.S., following the 2023 approval of Ipsen’s Sohonos.
August 20, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Checklist, Icon, Clipboard, List, Questionnaire
Gene therapy
Ultragenyx bags first gene therapy approval as previously rejected Sanfilippo asset awaits decision
The accelerated greenlight for Ultragenyx’s gene therapy for glycogen storage disease has raised analyst expectations for approval of UX111, which the FDA rejected last summer and is currently reviewing for a second time. A decision is expected by mid-September.
August 20, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Stairs Leading to Flying Paper Plane - Success, Growth, and Freedom, 3D Render
Cancer
Moderna stock nearly doubles as Merck-partnered mRNA cancer vaccine meets Phase 3 goal
Melanoma was slower to recur in patients receiving Merck and Moderna’s mRNA vaccine with Keytruda, supporting use of the combination in adjuvant treatment. The partners plan to take the data to the FDA.
August 19, 2026
 · 
3 min read
 · 
Nick Paul Taylor
Obesity
Enveda’s exercise-simulating obesity tablet clears early clinical test
Touting an “exceptional” gastrointestinal safety profile for its oral obesity drug candidate in a study of healthy volunteers, Enveda plans to test the asset in people stopping GLP-1 treatment.
August 19, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Sleeping girl in the pill bottles. concept of pills, good sleep, Insomnia, exhausted and frustrated
Neuroscience
Takeda leads wave of orexin drugs with potential to upend narcolepsy market
The FDA’s August approval of Takeda’s Orzeyful for treating the full set of narcolepsy symptoms initiated a new era in the sleep market.
August 19, 2026
 · 
5 min read
 · 
Nick Paul Taylor
Business negotiation, deal making or acquisition, merger vector concept. Two men shaking hands. Minimal design. Eps10 illustration
Manufacturing
Sandoz inks $322M Henlius deal for rights to as many as 10 biosimilars
The initial batch of biosimilars includes copies of Amgen, Eli Lilly and GSK drugs that collectively generate billions of dollars in annual revenues.
August 18, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Neon arrow sign showing a jumbo reversal of fortune
Manufacturing
Rebounding biotech funds expected to spur CDMO growth within year
With demand for pharma services historically lagging changes in biotech funding, analysts expect CDMOs to experience an uptick in activity in late 2026 or early 2027.
August 18, 2026
 · 
2 min read
 · 
Nick Paul Taylor
world map with red and orange colors over a dark color illustrations background
Manufacturing
Nascent US psychedelic therapy opportunity attracts overseas manufacturers
Companies that manufacture MDMA and psilocybin for patients in other countries are looking to use their experience to access the potential U.S. market.
August 14, 2026
 · 
4 min read
 · 
Nick Paul Taylor
Email envelope with warning sign on white background
Manufacturing
Scholar Rock rejigs approval filing after FDA flags violations at Novo plant
Despite earlier claims of improvement at the fill-finish plant, the FDA has classified the facility as Official Action Indicated based on inspection findings.
August 11, 2026
 · 
2 min read
 · 
Nick Paul Taylor
High angle night view of the city skyline at Huaian Bridge in Shijiazhuang, Hebei Province, China
Manufacturing
AstraZeneca partners with CSPC to build Chinese biologics manufacturing plant
News of the joint venture comes months after AstraZeneca vowed to spend $15 billion in China by the end of the decade.
August 10, 2026
 · 
2 min read
 · 
Nick Paul Taylor
A crushing blow to business and economic growth. Stopping income rise and welfare growth. Mitigate dangers and reduce risks. Anticipate the main blow of the crisis. End of career. Bankruptcy.
Earnings
BioNTech cuts sales forecast on slumping demand for COVID-19 vaccine
Lower vaccine demand across every market and more acute pressures in Germany led BioNTech to lower the midpoint of its sales outlook by almost 20%.
August 4, 2026
 · 
2 min read
 · 
Nick Paul Taylor
3D rendering of a GLP-1 agonist injector pen, a weight loss medication, with a medical measuring tape or ruler spiraling dynamically around its form.
Deals
Lilly and Resilience invest $750M in diabetes and obesity drug device supply
The investment will expand Resilience’s U.S. capacity to make the KwikPen device Eli Lilly uses to deliver its injectable diabetes and obesity medicines.
July 31, 2026
 · 
1 min read
 · 
Nick Paul Taylor
Pandoras box with smoke on a wooden background
Earnings
Regeneron’s ‘aversion’ to M&A questioned as bumper Q2 builds war chest
Calls for Regeneron to step up dealmaking have intensified as the company has established an $18 billion cash pile and suffered clinical trial setbacks.
July 30, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Two connecting arrows symbolizing artificial intelligence and humans working together to achieve a common goal, isolated on a light digital abstract background. Vector illustration.
Manufacturing
Kyverna taps ElevateBio to secure commercial supply of autoimmune CAR T therapy
ElevateBio will be the primary source of Kyverna’s autologous CAR T cell therapy for anticipated U.S. and global launches in autoimmune indications.
July 29, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Business handshake trendy halftone art collage banner template. Partnership concept, successful agreement, closing a deal, securing a contract. Modern retro cut out vector illustration
Manufacturing
Repligen strikes $1.5B BioLife buyout to bag cell therapy product pharmas rely on
Top-selling cell therapies from BMS, J&J and Gilead depend on a BioLife product, positioning Repligen to use the takeover to increase its exposure to the modality.
July 22, 2026
 · 
2 min read
 · 
Nick Paul Taylor